@palmview956oficial's TRT claims mostly check out

What did @palmview956oficial actually say?

The video follows a patient called Pablo getting testosterone pellets implanted at a med spa. The nurse practitioner on camera, who identifies herself as a family NP, says Pablo's testosterone was 465 ng/dL and that she's replacing it with "2,000 milligrams of testosterone today." She lists the benefits as improved mood, libido, fatigue, irritability, brain fog, and cardiovascular health. She also explains pellets release hormone steadily over about six months, which she positions as an advantage over injections and creams.

The procedure itself is shown: subcutaneous implantation in the gluteal/hip area with lidocaine numbing, followed by post-care instructions including no exercise or swimming for five days and keeping the site clean. The clinical framing is that age, stress, and anxiety drove his levels down, and pellets are the fix.

Does the science back this up?

Some of it, yes. The steady-state delivery claim for pellets is real, and the symptom list is consistent with hypogonadism literature. But the dose mentioned, 2,000mg, is where this gets genuinely concerning, and the framing of 465 ng/dL as needing treatment is worth scrutinizing hard.

The American Urological Association defines hypogonadism as total testosterone consistently below 300 ng/dL, with symptoms present (Mulhall et al., 2018, Journal of Urology). A level of 465 ng/dL falls squarely in the normal reference range for most labs (270-1070 ng/dL). Pellet dosing for men typically ranges from 600mg to 1,200mg per insertion cycle in published protocols (Donovitz, 2021, Cogent Medicine). A 2,000mg starting dose sits above the upper range of standard published protocols, and no peer-reviewed clinical trial was cited to support it. The cardiovascular benefit claim is complicated, which we'll get to.

What did they get wrong (or right)?

Let's be direct about both.

What they got right

• Pellets do produce more stable serum levels than weekly injections or topical creams. A 2012 study by Handelsman and Zajac (Australian Prescriber) confirmed subcutaneous implants maintain steadier pharmacokinetics than ester injections.
• The post-procedure care instructions, no swimming, no exercise, keep it clean, are standard and appropriate.
• Lidocaine buffered with bicarbonate for comfort is a legitimate clinical technique that reduces injection-site pain (Cepeda et al., 2010, Annals of Emergency Medicine).

What they got wrong

• Calling 465 ng/dL a level that warrants replacement is misleading without more clinical context. One reading, no symptom checklist shown, no second confirmatory test, which guidelines require.
• "2,000 milligrams of testosterone today" as a starting dose is above standard published pellet protocols. This is not a trivial discrepancy. Supraphysiologic dosing carries real risks including erythrocytosis, elevated hematocrit, and cardiovascular strain (Jones et al., 2011, European Journal of Endocrinology).
• The cardiovascular health claim is genuinely contested. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found testosterone therapy was non-inferior to placebo for major cardiovascular events in men with hypogonadism, but that study was not designed around hormone-optimization patients with normal baseline levels. Claiming a general heart benefit is premature.

What should you actually know?

If you're watching this and thinking about pellets, here's what the research actually supports, and where the gaps are.

Testosterone replacement therapy has legitimate clinical uses. Men with confirmed hypogonadism, two morning blood draws below 300 ng/dL plus symptoms, can see real improvements in energy, libido, and body composition (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). The pellet delivery method is FDA-cleared and the stable-level advantage is real for some patients.

What this video glosses over: starting TRT at a normal testosterone level is not the same as treating a deficiency. The "optimization" framing used at many med spas is not the same clinical category as treating hypogonadism, and the evidence base for treating men with levels in the 400-500 ng/dL range is thin. The dose stated here also warrants scrutiny from any prescribing clinician reviewing this content. A patient watching this video should not interpret it as a template for their own care.